Patents by Inventor Christian Darimont-Nicolau

Christian Darimont-Nicolau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180338942
    Abstract: Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes.
    Type: Application
    Filed: February 8, 2018
    Publication date: November 29, 2018
    Inventors: Christophe Moinard, Gabrielle Ventura, Denis Breuille, Christian Darimont-Nicolau, Luc Cynober
  • Patent number: 9962415
    Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: May 8, 2018
    Assignee: Nestec S.A.
    Inventors: Christian Darimont-Nicolau, Bernard Berger, Enea Rezzonico, Catherine Ngom-Bru, Melissa LePage
  • Patent number: 9913818
    Abstract: The present disclosure relates generally to compositions that comprise citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of metabolic syndrome, hyperglycemia, and/or hyperinsulinemia.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: March 13, 2018
    Assignee: Nestec S.A.
    Inventors: Christophe Moinard, Gabrielle Ventura, Denis Breuille, Christian Darimont-Nicolau, Luc Cynober
  • Publication number: 20160235699
    Abstract: The present disclosure relates generally to compositions that comprise citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of metabolic syndrome, hyperglycemia, and/or hyperinsulinemia.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 18, 2016
    Inventors: Christophe Moinard, Gabrielle Ventura, Denis Breuille, Christian Darimont-Nicolau, Luc Cynober
  • Publication number: 20160168627
    Abstract: The present invention relates to predicting the risk of developing hypertriglyceridemia in a subject by quantitating the amount of enterobacteria, e.g., E. coli, in the subject's gastrointestinal system. The invention also relates to treating a subject with hypertriglyceridemia or at risk of having the condition.
    Type: Application
    Filed: June 24, 2014
    Publication date: June 16, 2016
    Inventors: Chieh Jason Chou, Christian Darimont-Nicolau, Mathieu Membrez
  • Publication number: 20160089404
    Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.
    Type: Application
    Filed: May 1, 2014
    Publication date: March 31, 2016
    Inventors: Christian Darimont-Nicolau, Bernard Berger, Enea Rezzonico, Catherine Ngom-Bru, Melissa LePage
  • Publication number: 20150057344
    Abstract: The present invention generally relates to health benefits of natural compounds. In particular, the present invention relates peltatins, a group of natural compounds that can be used to treat, prevent or alleviate chronic inflammatory disorders. For example, the present invention concerns a composition comprising at least one peltatin for use in the treatment or prevention of chronic inflammatory disorders.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Inventors: Mohamed Nabil Bosco, Christian Darimont-Nicolau, Jalil Benyacoub
  • Publication number: 20150045425
    Abstract: The present invention relates to the field of metabolic disorders and aims to identify natural compounds that can be used effectively in this field. In particular, the present invention provides a composition comprising at least one peltatin for use in the treatment or prevention of metabolic disorders or risk factors thereof.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 12, 2015
    Inventors: Mohamed Nabil Bosco, Christian Darimont-Nicolau, Jalil Benyacoub
  • Patent number: 8710003
    Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: April 29, 2014
    Assignee: Nestec S.A.
    Inventors: Raylene Alison Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
  • Patent number: 8454949
    Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus helveticus CNCM I-4095 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: June 4, 2013
    Assignee: Nestec S.A.
    Inventors: Fabrizio Arigoni, Christian Darimont-Nicolau, Catherine Mace
  • Patent number: 8318151
    Abstract: The present invention generally relates to the field of weight management and obesity. In particular the present invention relates to the use of probiotics in combination with prebiotics to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus NCC 4007 in combination with a specific probiotic mixture for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: November 27, 2012
    Assignee: Nestec S.A.
    Inventors: Christian Darimont-Nicolau, David Philippe, Catherine Mace, Fabrizio Arigoni
  • Patent number: 8318150
    Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus CNCM I-4096 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: November 27, 2012
    Assignee: Nestec S.A.
    Inventors: Fabrizio Arigoni, Christian Darimont-Nicolau, Catherine Mace
  • Publication number: 20120039852
    Abstract: The present invention generally relates to the field of weight management and obesity. In particular the present invention relates to the use of probiotics in combination with prebiotics to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus NCC 4007 in combination with a specific probiotic mixture for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.
    Type: Application
    Filed: February 4, 2010
    Publication date: February 16, 2012
    Applicant: NESTEC S.A.
    Inventors: Christian Darimont-Nicolau, David Philippe, Catherine Mace, Fabrizio Arigoni
  • Publication number: 20110293569
    Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus CNCM I-4096 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.
    Type: Application
    Filed: February 4, 2010
    Publication date: December 1, 2011
    Applicant: NESTEC S.A.
    Inventors: Fabrizio Arigoni, Christian Darimont-Nicolau, Catherine Mace
  • Publication number: 20110293568
    Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus helveticus CNCM I-4095 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.
    Type: Application
    Filed: February 4, 2010
    Publication date: December 1, 2011
    Applicant: NESTEC S.A.
    Inventors: Fabrizio Arigoni, Christian Darimont-Nicolau, Catherine Mace
  • Publication number: 20100297253
    Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.
    Type: Application
    Filed: May 18, 2010
    Publication date: November 25, 2010
    Inventors: Raylene Alison REIMER, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
  • Publication number: 20100203174
    Abstract: The invention relates to a pet food composition for regulating body weight and preventing obesity and related disorders in pets, which comprises as an active ingredient at least one plant or plant extract having the ability to stimulate energy expenditure and/or fat burning. The invention also relates to a method for improving the health of pets, particularly by preventing obesity and metabolic disorders associated with obesity in pets. It also relates to a method for increasing energy expenditure, controlling the glucose homeostasis and improving activity or mobility of the pet.
    Type: Application
    Filed: April 15, 2010
    Publication date: August 12, 2010
    Applicant: NESTEC S.A.
    Inventors: Bernard Lemaure, Christian Darimont-Nicolau
  • Patent number: 7585618
    Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: September 8, 2009
    Assignee: Nestec S.A.
    Inventors: Raylene Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
  • Patent number: 7202082
    Abstract: The present invention relates to novel immortalized pre-osteoblast cell lines derived from the periost and capable of differentiate to osteoblasts. In particular, the present invention pertains to the use of such cell lines in assays for detecting substances controlling the differentiation of pre-osteoblasts to osteoblasts and for detecting substances enabling improved bone formation, maintenance of bone mass, bone repair and for preventing the onset of osteoporosis.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: April 10, 2007
    Assignee: Nestec S.A.
    Inventors: Elizabeth Offord Cavin, Christian Darimont-Nicolau, Catherine Mace
  • Publication number: 20050186558
    Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.
    Type: Application
    Filed: April 19, 2005
    Publication date: August 25, 2005
    Inventors: Raylene Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser